Cimetropium

DB09271InvestigationalSmall molecule

Cimetropium is a semi-synthetic belladonna alkaloid and derivative of scopolamine. It is a potent antimuscarinic and an effective antispasmodic drug. It is also endowed of a direct myolitic action which... It has never been approved for use in the U.S. or Canada.

Formula / weight: C₂₁H₂₈NO₄ · 358.457 g/mol (avg)
Also known as: Cimetropium ion

Resolves to

Compound

UNII1N3H74AYTKCAS150521-16-7ChEMBLCHEMBL2110773ChEBI135516PubChem20054871KEGGD07099

Clinical / RWD

ATCA03BB05

Structure

InChIKeyQVVOZYKELHAIPX-WVHCHWADSA-NSMILES[H][C@](CO)(C(=O)O[C@@]1([H])C[C@@]2([H])[C@]3([H])O[C@]3([H])[C@@]([H])(C1)[N+]2(C)CC1CC1)C1=CC=CC=C1

Targets

P08912CHRM5

What you can answer from here — as of August 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

135Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

5Marketed productsAcross 1 country and 1 labeller

1ATC codeIncluding every combination product, plus 11 drug categories

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Cimetropium, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account